Featured News - Current News - Archived News - News Categories

Research ties common heartburn medications to kidney disease, failure

Submitted

Tue, Mar 19th 2019 11:00 am

Study examines 190,000 patients over 15 years, finds acid reflux drugs increase risk of kidney disease by 20 percent

By the University at Buffalo

Common medications prescribed to treat heartburn, acid reflux and ulcers are linked to increased risks for kidney failure and chronic kidney disease, a recent University at Buffalo study has found.

Use of proton pump inhibitors (PPI), a group of drugs that reduce the production of stomach acid, increases the risk of chronic kidney disease by 20 percent and raises the risk of kidney failure by four times. Risks were highest among people at least 65 years old.

The research, published in February in Pharmacotherapy, is one of the first large, long-term studies to examine the effects of PPIs on kidney function. Researchers examined the health data of more than 190,000 patients over a 15-year period.

“This study adds to a growing list of concerning side effects and adverse outcomes associated with PPIs,” said David Jacobs, Pharm.D., Ph.D., lead investigator and assistant professor of pharmacy practice in the UB School of Pharmacy and Pharmaceutical Sciences. “Given the increasing global use of PPIs, the relationship between PPIs and renal disease could pose a substantial disease and financial burden to the health care system and public health.”

PPIs are one of the most commonly prescribed medications in the U.S., with an estimated 113 million prescriptions filled in 2008, costing patients nearly $14 billion, Jacobs said.

Due to acid reflux and related conditions only requiring short-term treatment with PPIs, he added, up to 70 percent of patients overuse these medications without benefit and are subjected to unnecessary adverse effects.

The prevalence of PPI use in the U.S. could have a devastating effect on public health. Because these drugs are still considered safe, education and deprescribing initiatives are needed to raise awareness among health care providers, Jacobs noted. Deprescribing may involve reducing dosage or stopping usage.

Data for the investigation was gathered from medical insurance and prescription claims from a Western New York insurer. Researchers examined medical history from 1993-2008 of adult patients with no history of kidney disease.

Kidney health was compared between patients who underwent PPI therapy and those who were unexposed. Examined PPIs included esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole (commonly known by brand names as Vimovo, Prevacid, Prilosec, Protonix and Aciphex, respectively).

Additional School of Pharmacy and Pharmaceutical Sciences investigators included Terry Dunn, Pharm.D., clinical assistant professor; Steven Feuerstein, data analyst; and Pharm.D. student Emily Hart.

comments powered by Disqus

Hometown News